Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > So true.....salutations to A'holes here

<< Previous

Bullboard Posts

Next >>

Comment by Doccoleon Aug 07, 2021 12:59pm

260 Views

Post# 33668435

RE:So true.....salutations to A'holes here

That's great!

what a rollercoaster this last week!

bad news to start the week then a lil rebound....the ATE mob has been going everywhich direction.

I am far from a expert with all this. I think with the pause /delay it's officially all over my head. I do know this management team is slow to do anything. They enjoy their salaries and atta boy shares. Why rush.

Hopefully we will get some direction from Dano and less love letters to share holders.

White knuckling this sucker!

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China